Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.60 |
| ▸ | TMIGD3 | P0DMS9 | 7/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160392 | 0.88 | ADORA2A (0.67) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5162867 | 0.86 | ADORA2A (0.69) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5161863 | 0.85 | ADORA2A (0.68) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5161570 | 0.84 | ADORA2A (0.67) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5158649 | 0.84 | ADORA2A (0.67) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5161859 | 0.84 | ADORA2A (0.58) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5160867 | 0.84 | ADORA2A (0.83) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5159031 | 0.82 | ADORA2A (0.64) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5164010 | 0.78 | ADORA2A (0.84) | ADORA2AADORA2BADORA1TMIGD3ADORA3 | |
| SCHEMBL5159063 | 0.77 | ADORA2A (0.43) | ADORA2AADORA2BADORA1TMIGD3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1456209-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.